Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:11 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT01812005 · Ohio State University Comprehensive Cancer Center · PHASE2 · terminated · last registry update 2018-06-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow patient enrollment and study discontinued after 14 patients enrolled” | – | Registry record, Ohio State University Comprehensive Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AURKA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-05-31Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib (NCT00697346)
- 2019-05-02Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib + Paclitaxel (NCT02367352)
- 2019-03-25Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib + Esomeprazole (NCT01844583)
- 2019-03-15Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib (NCT01512758)
- 2019-03-15Results posted on the registry: Millennium Pharmaceuticals, Inc., alisertib (NCT00651664)
- 2019-03-14Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib (NCT00500903)
- 2019-03-12Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib (NCT00962091)
- 2019-02-15Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib + Docetaxel (NCT01094288)
- 2018-12-27Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib + Placebo (NCT02038647)
- 2018-11-15Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib (NCT02214147)
- 2018-11-09Results posted on the registry: Merck Sharp & Dohme LLC, MK-5108 + docetaxel (NCT00543387)
- 2018-10-31Results posted on the registry: Millennium Pharmaceuticals, Inc., [^14C]-alisertib + alisertib (NCT01714947)
- 2018-10-11Results posted on the registry: Massachusetts General Hospital, Alisertib + Cytarabine (NCT02560025)
- 2018-07-31Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib + Pralatrexate (NCT01482962)
- 2018-07-27Also stopped (withdrawn): Eric Bernicker, MD, Brentuximab Vedotin + Alsertib (NCT02780011)
- 2018-06-04Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib + Paclitaxel (NCT01091428)
- 2018-05-17Also stopped (terminated): Fox Chase Cancer Center, MLN8237 and Erlotinib (NCT01471964)
- 2018-05-11Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib (NCT00830518)
- 2018-03-27Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib (NCT00853307)
- 2018-03-27Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib (NCT00807495)
- 2018-03-27Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib (MLN8237) + Rituximab (NCT01397825)
- 2017-12-06Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Alisertib + Abiraterone acetate (NCT01848067)
- 2017-11-29Results posted on the registry: Weill Medical College of Cornell University, MLN8237 (NCT01799278)
- 2017-11-20Also stopped (terminated): UNC Lineberger Comprehensive Cancer Center, Alisertib (NCT02700022)
- 2017-11-07Results posted on the registry: University Health Network, Toronto, ENMD-2076 (NCT01719744)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision